LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates June 22, 2021 2021, Press Releases
Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression September 30, 2019 2019
